Martin T Freitag1, Claudia Kesch2, Jens Cardinale3, Paul Flechsig4, Ralf Floca5, Matthias Eiber6, David Bonekamp7, Jan P Radtke2, Clemens Kratochwil4, Klaus Kopka3, Markus Hohenfellner2, Albrecht Stenzinger8, Heinz-Peter Schlemmer7, Uwe Haberkorn4,9, Frederik Giesel4. 1. Department of Radiology, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, Germany. m.freitag@dkfz.de. 2. Department of Urology, University Hospital Heidelberg, Heidelberg, Germany. 3. Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany. 4. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. 5. Medical Image Computing Group, German Cancer Research Center, Heidelberg, Germany. 6. Department of Nuclear Medicine, Technical University Hospital Munich, Munich, Germany. 7. Department of Radiology, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, Germany. 8. Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. 9. Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany.
Abstract
INTRODUCTION: The aim of the present study was to explore the clinical feasibility and reproducibility of a comprehensive whole-body 18F-PSMA-1007-PET/MRI protocol for imaging prostate cancer (PC) patients. METHODS: Eight patients with high-risk biopsy-proven PC underwent a whole-body PET/MRI (3 h p.i.) including a multi-parametric prostate MRI after 18F-PSMA-1007-PET/CT (1 h p.i.) which served as reference. Seven patients presented with non-treated PC, whereas one patient presented with biochemical recurrence. SUVmean-quantification was performed using a 3D-isocontour volume-of-interest. Imaging data was consulted for TNM-staging and compared with histopathology. PC was confirmed in 4/7 patients additionally by histopathology after surgery. PET-artifacts, co-registration of pelvic PET/MRI and MRI-data were assessed (PI-RADS 2.0). RESULTS: The examinations were well accepted by patients and comprised 1 h. SUVmean-values between PET/CT (1 h p.i.) and PET/MRI (3 h p.i.) were significantly correlated (p < 0.0001, respectively) and similar to literature of 18F-PSMA-1007-PET/CT 1 h vs 3 h p.i. The dominant intraprostatic lesion could be detected in all seven patients in both PET and MRI. T2c, T3a, T3b and T4 features were detected complimentarily by PET and MRI in five patients. PET/MRI demonstrated moderate photopenic PET-artifacts surrounding liver and kidneys representing high-contrast areas, no PET-artifacts were observed for PET/CT. Simultaneous PET-readout during prostate MRI achieved optimal co-registration results. CONCLUSIONS: The presented 18F-PSMA-1007-PET/MRI protocol combines efficient whole-body assessment with high-resolution co-registered PET/MRI of the prostatic fossa for comprehensive oncological staging of patients with PC.
INTRODUCTION: The aim of the present study was to explore the clinical feasibility and reproducibility of a comprehensive whole-body 18F-PSMA-1007-PET/MRI protocol for imaging prostate cancer (PC) patients. METHODS: Eight patients with high-risk biopsy-proven PC underwent a whole-body PET/MRI (3 h p.i.) including a multi-parametric prostate MRI after 18F-PSMA-1007-PET/CT (1 h p.i.) which served as reference. Seven patients presented with non-treated PC, whereas one patient presented with biochemical recurrence. SUVmean-quantification was performed using a 3D-isocontour volume-of-interest. Imaging data was consulted for TNM-staging and compared with histopathology. PC was confirmed in 4/7 patients additionally by histopathology after surgery. PET-artifacts, co-registration of pelvic PET/MRI and MRI-data were assessed (PI-RADS 2.0). RESULTS: The examinations were well accepted by patients and comprised 1 h. SUVmean-values between PET/CT (1 h p.i.) and PET/MRI (3 h p.i.) were significantly correlated (p < 0.0001, respectively) and similar to literature of 18F-PSMA-1007-PET/CT 1 h vs 3 h p.i. The dominant intraprostatic lesion could be detected in all seven patients in both PET and MRI. T2c, T3a, T3b and T4 features were detected complimentarily by PET and MRI in five patients. PET/MRI demonstrated moderate photopenic PET-artifacts surrounding liver and kidneys representing high-contrast areas, no PET-artifacts were observed for PET/CT. Simultaneous PET-readout during prostate MRI achieved optimal co-registration results. CONCLUSIONS: The presented 18F-PSMA-1007-PET/MRI protocol combines efficient whole-body assessment with high-resolution co-registered PET/MRI of the prostatic fossa for comprehensive oncological staging of patients with PC.
Entities:
Keywords:
18F-PSMA-1007; 68Ga-PSMA-11; PET/MRI; PSMA; PSMA-PET; Prostate cancer
Authors: Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper Journal: Clin Cancer Res Date: 2011-10-31 Impact factor: 12.531
Authors: A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke Journal: Eur J Nucl Med Mol Imaging Date: 2013-12-19 Impact factor: 9.236
Authors: Martin T Freitag; Jan P Radtke; Ali Afshar-Oromieh; Matthias C Roethke; Boris A Hadaschik; Martin Gleave; David Bonekamp; Klaus Kopka; Matthias Eder; Thorsten Heusser; Marc Kachelriess; Kathrin Wieczorek; Christos Sachpekidis; Paul Flechsig; Frederik Giesel; Markus Hohenfellner; Uwe Haberkorn; Heinz-Peter Schlemmer; A Dimitrakopoulou-Strauss Journal: Eur J Nucl Med Mol Imaging Date: 2016-12-17 Impact factor: 9.236
Authors: Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper Journal: Mol Imaging Biol Date: 2015-08 Impact factor: 3.488
Authors: Jan Philipp Radtke; Boris A Hadaschik; Maya B Wolf; Martin T Freitag; Constantin Schwab; Celine Alt; Wilfried Roth; Stefan Duensing; Sascha A Pahernik; Matthias C Roethke; Heinz-Peter Schlemmer; Markus Hohenfellner; Dogu Teber Journal: J Endourol Date: 2015-08-20 Impact factor: 2.942
Authors: Thorsten Heußer; Philipp Mann; Christopher M Rank; Martin Schäfer; Antonia Dimitrakopoulou-Strauss; Heinz-Peter Schlemmer; Boris A Hadaschik; Klaus Kopka; Peter Bachert; Marc Kachelrieß; Martin T Freitag Journal: PLoS One Date: 2017-08-17 Impact factor: 3.240
Authors: Frederik L Giesel; B Hadaschik; J Cardinale; J Radtke; M Vinsensia; W Lehnert; C Kesch; Y Tolstov; S Singer; N Grabe; S Duensing; M Schäfer; O C Neels; W Mier; U Haberkorn; K Kopka; C Kratochwil Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-26 Impact factor: 9.236
Authors: Jens Cardinale; René Martin; Yvonne Remde; Martin Schäfer; Antje Hienzsch; Sandra Hübner; Anna-Maria Zerges; Heike Marx; Ronny Hesse; Klaus Weber; Rene Smits; Alexander Hoepping; Marco Müller; Oliver C Neels; Klaus Kopka Journal: Pharmaceuticals (Basel) Date: 2017-09-27
Authors: Laura Evangelista; Fabio Zattoni; Gianluca Cassarino; Paolo Artioli; Diego Cecchin; Fabrizio Dal Moro; Pietro Zucchetta Journal: Eur J Nucl Med Mol Imaging Date: 2020-09-08 Impact factor: 9.236
Authors: Christopher C Khoo; Saiful Miah; Martin J Connor; Joseph Tam; Mathias Winkler; Hashim U Ahmed; Taimur T Shah Journal: Transl Androl Urol Date: 2020-06
Authors: Felipe de Galiza Barbosa; Marcelo Araújo Queiroz; Rafael Fernandes Nunes; José Flávio Gomes Marin; Carlos Alberto Buchpiguel; Giovanni Guido Cerri Journal: Clinics (Sao Paulo) Date: 2018-09-21 Impact factor: 2.365